On April 27, 2026, Revolution Medicines sent a letter to Erasca alleging that ERAS-0015 infringes U.S. Patent No. 12,409,225 under the doctrine of equivalents and involves trade secret misappropriation by a third party.12
Revolution demands Erasca cease all activities related to ERAS-0015, potentially halting its clinical trials.13
Erasca plans to vigorously defend against the claims, expressing confidence in its IP, with analysts maintaining Buy ratings.126
ERAS-0015 is a pan-RAS molecular glue showing promising early results:
40% tumor shrinkage in pancreatic cancer and 62% in KRAS-mutant NSCLC.5
Market reaction:
Erasca shares dropped 7-9% to $19.49, amid ongoing AURORAS-1 trial progress.12
Sources:
1. https://www.gurufocus.com/news/8820137/erasca-eras-faces-legal-challenge-over-patent-claims
2. https://intellectia.ai/news/stock/erasca-inc-faces-allegations-of-trade-secret-misappropriation-from-revolution-medicines-concerning-eras0015--sec-filing
3. https://www.tipranks.com/news/the-fly/erasca-sinks-after-revolution-medicines-alleges-patent-infringement-thefly-news
5. https://www.statnews.com/2026/04/27/erasca-pancreatic-cancer-study-results/
6. https://www.ainvest.com/news/erasca-intends-contest-revolution-medicines-allegations-2604/